Over The Counter 24 May 2022: US OTC Monograph Reform And A 'Faster Moving FDA’ With CHPA’s Barbara Kochanowski and David Spangler
Executive Summary
In this episode, HBW Insight speaks to Barbara Kochanowski and David Spangler of the US Consumer Healthcare Products Association about OTC monograph reform. The OTC monograph program was reimagined as a part of the 2020 CARES act passed in the early stages of the pandemic. While the changes were designed to streamline and modernize the program, results have been slow with the FDA's attention focused on tackling COVID-19. But as the agency hires more staff, Spangler says he expects to see a "faster moving FDA" in the next three years. Spangler and Kochanowski also discuss the efficacy of the monograph reforms and how CHPA has helped educate its members about the changes.
You may also be interested in...
FDA Warns Eye Care Company Conducting Unapproved Clinical Trial Of Drug-Device Product
The FDA sent a warning letter to Arbor Center for EyeCare for failing to submit an IND before beginning a trial of a novel drug-device combination product.
Color Additive Risk Evaluation Tool Qualified As New Medical Device Development Tool
A color additive evaluation tool for polymeric medical devices was approved as an MDDT under the FDA’s voluntary program.
Sterigenics Wins Second Lawsuit In Ongoing Ethylene Oxide Court Battles
In the second trial over Sterigenics’ ethylene oxide plant emissions, the Cook County, IL jury found Stergiencs not liable for cancer in a woman who lived near the plant.